Phone : 1-415-349-0054 Toll Free : 1-888-202-9519 Email : sales @ radiantinsights . com Web : http :// www . radiantinsights . com /
Request A Sample Copy Of This Report at : http :// www . radiantinsights . com / research / frontier-pharma-type-2-diabetes-mellitus-gpcrsand-protein-kinases-dominate-pipeline / request-sample
Reason to Buy :
This report will allow you to -
‣ Appreciate the current clinical and commercial landscapes by considering disease pathogenesis , etiology , epidemiology , symptoms , co-morbidities and complications , and treatment options . Identify leading products and companies within the market , as well as key unmet needs , in order to gain a competitive understanding of gaps in the current market .
‣ Recognize innovative pipeline trends by analyzing therapies by stage of development , molecule type and molecular target .
‣ Assess the therapeutic potential of first-in-class targets . Using a proprietary matrix , all firstin-class targets in the T2DM pipeline have been assessed and ranked according to clinical potential . Promising early-stage targets have been further reviewed in greater detail .
‣ Consider first-in-class pipeline products with no prior involvement in licensing and codevelopment deals that may represent potential investment opportunities .
Scope :
The escalating T2DM public healthcare need has resulted in a competitive market landscape
‣ What is the pathophysiology of T2DM ?
‣ What are the common co-morbidities and complications ?
‣ How has the emergence of new drug classes in the past decade impacted the treatment algorithm ?
‣ What are the most significant unmet needs within the market ?
The T2DM pipeline is large and innovative
‣ Which molecule types and molecular targets are most prominent within the pipeline ?
‣ Which first-in-class targets are most promising ?
‣ How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class ?
The T2DM deals landscape is highly active
‣ Do T2DM products attract high deal values ?
‣ Which molecule types and molecular targets dominate the deals landscape ?
‣ Which first-in-class pipeline products have no prior involvement in licensing or codevelopment deals ?
https
:// www . facebook . com / RadiantInsights
https :// www . linkedin . com / company / radiant-insights https :// twitter . com / radiantinsights
https :// plus . google . com /+ Radiantinsights